Phase II study of cediranib in patients with Malignant pleural mesothelioma: SWOG S0509

Journal of Thoracic Oncology

Volumn 6, Issue 11, 2011, Pages 1938-1945

  Garland, Linda L ^a   Chansky, Kari ^b   Wozniak, Antoinette J ^c   Tsao, Anne S ^d   Gadgeel, Shirish M ^c   Verschraegen, Claire F ^e   Dasilva, Marco A ^f   Redman, Mary ^b   Gandara, David R ^g  

^a UNIVERSITY OF ARIZONA   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF NEW MEXICO   (United States)

^f Kingsport Hematology Oncology   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis inhibitor; Phase 2; Pleural mesothelioma

Indexed keywords

CEDIRANIB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMMONIA BLOOD LEVEL; ANEMIA; ANOREXIA; APNEA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; BRAIN DISEASE; CANCER GROWTH; CANCER MORTALITY; CANCER PAIN; CANCER SIZE; CANCER SURVIVAL; COGNITIVE DEFECT; COLITIS; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DEHYDRATION; DETERIORATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG RESPONSE; EMBOLISM; ESOPHAGUS NECROSIS; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEADACHE; HEARTBURN; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOTHYROIDISM; INTESTINAL PAIN; KIDNEY FAILURE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MONOTHERAPY; MUSCLE WEAKNESS; NAUSEA; NECROSIS; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SENSORY NEUROPATHY; SIDE EFFECT; SMALL INTESTINE PERFORATION; SPEECH DISORDER; SURVIVAL RATE; SURVIVAL TIME; THORAX PAIN; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; VISCERAL PAIN; VOICE CHANGE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 80054880979     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318229586e     Document Type: Article

References (44)

1. Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992;34:718-721.
2. Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol 2009;39:576-588.
3. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer 1999;79:666-672. (Pubitemid 29046253)
4. Kao SC, Reid G, Lee K, et al. Malignant mesothelioma. Intern Med J 2010;40:742-750.
5. Hodgson JT, McElvenny DM, Darnton AJ, et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005;92:587-593. (Pubitemid 40395543)
6. Martini N, McCormack PM, Bains MS, et al. Pleural mesothelioma. Ann Thorac Surg 1987;43:113-120. (Pubitemid 17004859)
7. Van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organization for Research and Treatment of Cancer Lung Cancer Group and the National Institute of Canada. J Clin Oncol 2005;23:6881-6889.
8. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-2644. (Pubitemid 46606305)
9. Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999;81:54-61. (Pubitemid 29415491)
10. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468-475. (Pubitemid 32266815)
11. Masood R, Kundra A, Zhu S, et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 2003;104:603-610. (Pubitemid 36337260)
12. Demirag F, Unsal E, Yilmaz A, et al. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest 2005;128:3382-3387. (Pubitemid 41698667)
13. Kumar-Singh S, Weyler J, Martin MJ, et al. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and-2, and TGF beta expression. J Pathol 1999;189:72-78. (Pubitemid 29406822)
14. Konig J, Tolnay E, Wiethege T, et al. Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma. Respiration 2000;67:36-40. (Pubitemid 30114163)
15. Edwards JG, Cox G, Andi A, et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 2001;85:863-868. (Pubitemid 33010554)
16. Heckman CA, Holopainen T, Wirzenius M, et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res 2008;68: 4754-4762.
17. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 ty-rosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65: 4389-4400. (Pubitemid 40775678)
18. Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:3045-3054. (Pubitemid 47218051)
19. Ryan CJ, Stadler WM, Roth B, et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs 2007; 25:445-451. (Pubitemid 47222908)
20. Yamamoto N, Tamura T, Yamamoto N, et al. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2009;64:1165-1172.
21. Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009;27:5601-5606.
22. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann.Oncol 2004;15:257-260. (Pubitemid 38262625)
23. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
24. Janne PA, Wozniak AJ, Belani CP, et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural me-sothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol 2006;1:506-512. (Pubitemid 47181396)
25. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26:1698-1704.
26. Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007;25:2406-2413. (Pubitemid 46999211)
27. Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008;113:808-814.
28. Mathy A, Baas P, Dalesio O, et al. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005;50:83-86. (Pubitemid 41297473)
29. Jahan TM, Gu L, Wang X, et al. Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30107). J Clin Oncol 2010;24(Suppl 18).
30. Janne PA, Wang XF, Krug LM, et al. Sorafenib in malignant mesothe-lioma (MM): a phase II trial of the Cancer and Leukemia Group B (CALGB 30307). J Clin Oncol 2010;25(Suppl 18).
31. Nowak AK, Millward MJ, Francis R, et al. Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). J Clin Oncol 2008;26(Suppl 15).
32. Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008;113:808-814.
33. Karrison T, Kindler HL, Gandara DR, et al. Final analysis of a multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabin/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioms (MM). J Clin Oncol 2007; 25(Suppl 18):7526 (abstract).
34. van Klaveren RJ, Aerts JG, de Bruin H, et al. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural me-sothelioma. Lung Cancer 2004;43:63-69. (Pubitemid 38096293)
35. Hofmann M, McCormack E, Mujic M, et al. Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumor model. Neoplasia 2009;11:812-822.
36. Klosowska-Wardega A, Hasumi Y, Burmakin M, et al. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. PLoS One 2009;4:e8149.
37. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147. (Pubitemid 38524883)
38. Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007;13:3942-3950. (Pubitemid 47037602)
39. Pietras K, Stumm M, Hubert M, et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003;9:3779-3787. (Pubitemid 37169248)
40. Pietras K, Rubin K, Sjoblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62:5476-5484.
41. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61: 2929-2934. (Pubitemid 32691937)
42. Goss G, Shepherd FA, Laurie S, et al. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Eur.J Cancer 2009;45:782-788.
43. Laurie SA, Gauthier I, Arnold A, et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2008;26:1871-1878.
44. Goss GD, Arnold A, Shepherd FA, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010;28:49-55.